Arcus Biosciences (NYSE:RCUS) said on Thursday that its experimental drug candidate, quemliclustat, has received orphan drug status from the U.S. FDA. Quemliclustat is a type of medication that works ...

Hayward, CA-based Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company with a market capitalization of $1.29 billion and a strong financial health rating according to ...

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. T ...

In this article, learn about arcus senilis. What are the risk factors, how is it diagnosed, how is it linked to high cholesterol, and can it be treated? Learn more.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Arcus Biosciences (RCUS) been one of those stocks this ...

Daina Graybosch’s rating is based on the anticipation of positive clinical outcomes and strategic management decisions concerning Arcus Biosciences.

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage ...

Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that ...

HAYWARD, Calif., January 21, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...